| 摘要 |
Disclosed is the use of potassium channel openers such as flupirtine in combination with sodium channel inhibiting substances selected from the group comprising tolperisone or its analogs eperisone or silperisone, or riluzole, propafenone, lidocaine, flecainide, metixene or their pharmaceutically acceptable salts for the manufacture of a medicament for the treatment of painful conditions associated with elevated muscle tone such as neuralgias, arthritis, chronic or episodic tension headache, lower spastic paraparesis syndrome, lower paraspasm, transverse myelitis , multiple sclerosis , hereditary inferior spastic paraplegia (Stuempel's paraplegia), impairments of the spinal blood circulation, cerebral paralysis with lower spastic paresis, tetraparesis associated with cervical myelopathy, cervical brachialgia, vertebral dysplasia or Parkinson's disease.
|
